Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy
US11697804B2 · kind B2 · utility
0Cited by
4References
35Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 1, 2019 |
| Grant date | Jul 11, 2023 |
| Priority date | — |
| Expiry date | Aug 20, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y207/01021
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A DNA plasmid useful for diagnostic and therapeutic gene therapy is disclosed. Improvements to gene therapy methods known in the art are provided to ensure cancer-targeting, high efficacy, and long durability of expression. The DNA plasmid is combined with compositions of polymeric nanoparticles for non-viral gene therapy to treat cancer, including hepatocellular carcinoma and prostate cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.